Abstract
Vascular endothelial growth factor (VEGF) is an endogenous polypeptide that modulates angiogenesis in normal physiological conditions as well as in cancer. During angiogenesis, VEGF interacts with several other angiogenic factors, playing an important role in cell proliferation, differentiation, migration, cell survival, nitric oxide (NO) production, release of other growth factors and sympathetic innervation. Based on these mechanisms of action, several anti-VEGF drugs have been developed for cancer treatment. This review discusses the physiology and interactions of VEGF, its mechanisms of action and role in modulating vascular homeostasis. It also discusses the adverse cardiovascular effects of recently developed anti-VEGF drugs for the treatment of various types of cancer. A critical appraisal of the human studies on these drugs is provided. Furthermore, putative mechanisms for the onset of hypertension, the most common adverse cardiovascular effect, are discussed.
Keywords: Vascular endothelial growth factor, angiogenesis, endothelium, homeostasis, cardiotoxicity, hypertension, nitric oxide, clinical trials, vascular endothelial growth factor receptor, renin angiotensin system, cytokines, interleukin
Current Vascular Pharmacology
Title: The Emerging Role of Vascular Endothelial Growth Factor (VEGF) in Vascular Homeostasis: Lessons from Recent Trials with Anti-VEGF Drugs
Volume: 9 Issue: 3
Author(s): Shivshankar Thanigaimani, Ganessan Kichenadasse and Arduino A. Mangoni
Affiliation:
Keywords: Vascular endothelial growth factor, angiogenesis, endothelium, homeostasis, cardiotoxicity, hypertension, nitric oxide, clinical trials, vascular endothelial growth factor receptor, renin angiotensin system, cytokines, interleukin
Abstract: Vascular endothelial growth factor (VEGF) is an endogenous polypeptide that modulates angiogenesis in normal physiological conditions as well as in cancer. During angiogenesis, VEGF interacts with several other angiogenic factors, playing an important role in cell proliferation, differentiation, migration, cell survival, nitric oxide (NO) production, release of other growth factors and sympathetic innervation. Based on these mechanisms of action, several anti-VEGF drugs have been developed for cancer treatment. This review discusses the physiology and interactions of VEGF, its mechanisms of action and role in modulating vascular homeostasis. It also discusses the adverse cardiovascular effects of recently developed anti-VEGF drugs for the treatment of various types of cancer. A critical appraisal of the human studies on these drugs is provided. Furthermore, putative mechanisms for the onset of hypertension, the most common adverse cardiovascular effect, are discussed.
Export Options
About this article
Cite this article as:
Thanigaimani Shivshankar, Kichenadasse Ganessan and A. Mangoni Arduino, The Emerging Role of Vascular Endothelial Growth Factor (VEGF) in Vascular Homeostasis: Lessons from Recent Trials with Anti-VEGF Drugs, Current Vascular Pharmacology 2011; 9 (3) . https://dx.doi.org/10.2174/157016111795495503
DOI https://dx.doi.org/10.2174/157016111795495503 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Ventricular Arrhythmias in Patients with Obstructive Sleep Apnea
Current Cardiology Reviews Heat Shock Proteins - Two Sides of a Coin
Current Cardiology Reviews Biogenic Peptides and Their Potential Use
Current Pharmaceutical Design Inflammation, Endothelial Dysfunction and Arterial Stiffness as Therapeutic Targets in Cardiovascular Medicine
Current Pharmaceutical Design The Effects of Olprinone, a Phosphodiesterase 3 Inhibitor, on Systemic and Cerebral Circulation
Current Vascular Pharmacology The Management of Dyslipidaemia in Patients with Type 2 Diabetes Mellitus Receiving Lipid-Lowering Drugs: A Sub-Analysis of the CEPHEUS Findings
Current Vascular Pharmacology Homocysteine and Heart Failure: An Overview
Recent Patents on Cardiovascular Drug Discovery Design and Ocular Tolerance of Flurbiprofen Loaded Nanosuspension
Pharmaceutical Nanotechnology Role of Iodine in Metabolism
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) EarlyVascularAgeing and Hypertension -A New Model for Understanding Cardiovascular Risk
Current Hypertension Reviews Polypeptide Toxins from Animal Venoms
Recent Patents on DNA & Gene Sequences Contemporary Pharmacologic Management of Heart Failure with Reduced Ejection Fraction: A Review
Current Cardiology Reviews Intravenous Antihypertensives within Cardiovascular-Based Continuity of Care
Current Vascular Pharmacology Lipoprotein(a): Current Perspectives
Current Vascular Pharmacology MicroRNAs: Novel Diagnostic and Prognostic Biomarkers in Atherosclerosis
Current Topics in Medicinal Chemistry The Impact of Inflammatory Profile on Selenium Levels in Hemodialysis Patients
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Bilayer Tablet Based Chronotherapeutics in the Management of Nocturnal Asthma: An Overview
Recent Patents on Drug Delivery & Formulation TRAIL as Biomarker and Potential Therapeutic Tool for Cardiovascular Diseases
Current Drug Targets The Use of 68Ga-DOTA-(Tyr3)-Octreotate PET/CT for Improved Target Definition in Radiotherapy Treatment Planning of Meningiomas – A Case Report
Current Radiopharmaceuticals Vitamin D/VDR in Acute Kidney Injury: A Potential Therapeutic Target
Current Medicinal Chemistry